Allogene Therapeutics, Inc. (ALLO) priced the previously announced $175 million public offering of 87.50 million shares at $2.00 per share. The offering is expected to close on or about April 16, 2026.
Also, Allogene has granted the underwriters a 30-day option to purchase up to 13.12 million additional shares.
Allogene expects to use the net proceeds from this offering for general corporate purposes, including clinical trials, research and development, general and administrative expenses, and capital expenditures.
The company is currently developing allogenic CAR-T (Allo CAR T) therapies to treat autoimmune and cancer indications, including lymphoma, small cell lung cancer (SCLC), gastric and pancreatic cancers.
Goldman Sachs & Co. LLC, Jefferies and TD Cowen are acting as joint bookrunners for the offering.
ALLO has traded between $0.86 and $4.46 over the last year. The stock closed Tuesday's trade at $2.28, down 25.37%.
In the overnight market, ALLO is down 6.14% at $2.14.
For More Such Biotech Stock News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.